Analysis of Profitability Ratios
Quarterly Data
Beginner level
Profitability ratios measure the company’s ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Illumina Inc., profitability ratios (quarterly data)
Based on: 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Illumina Inc.’s gross profit margin ratio improved from Q4 2019 to Q1 2020 but then slightly deteriorated from Q1 2020 to Q2 2020. |
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Illumina Inc.’s operating profit margin ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Illumina Inc.’s net profit margin ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Illumina Inc.’s ROE deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
| ROA | A profitability ratio calculated as net income divided by total assets. | Illumina Inc.’s ROA deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Gross Profit Margin
Illumina Inc., gross profit margin calculation (quarterly data)
| Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Jan 1, 2017 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | Jan 3, 2016 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Gross profit | 428 | 619 | 662 | 648 | 573 | 584 | 590 | 597 | 575 | 538 | 542 | 482 | 434 | 368 | 419 | 426 | 424 | 397 | 410 | 388 | 376 | 375 | |||||||
| Revenue | 633 | 859 | 952 | 907 | 838 | 846 | 868 | 853 | 830 | 782 | 778 | 714 | 662 | 598 | 619 | 607 | 600 | 572 | 592 | 550 | 539 | 539 | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| Gross profit margin1 | 70.34% | 70.36% | 69.63% | 69.24% | 68.84% | 69.06% | 69.01% | 69.44% | 68.85% | 67.98% | 66.35% | 65.68% | 66.26% | 67.53% | 69.48% | 69.91% | 69.96% | 69.74% | 69.80% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 50.97% | 52.13% | 52.46% | 52.39% | 52.17% | 51.57% | 51.32% | 50.57% | 50.38% | 49.39% | 47.75% | 48.59% | 49.21% | 51.32% | 54.09% | 54.17% | 53.99% | 53.93% | 54.19% | — | — | — | |||||||
| AbbVie Inc. | 73.56% | 77.43% | 77.64% | 77.32% | 77.41% | 77.07% | 76.44% | 75.22% | 74.93% | 75.18% | 75.05% | 76.85% | 76.78% | 76.81% | 77.25% | 77.21% | 78.12% | 79.28% | 80.31% | — | — | — | |||||||
| Amgen Inc. | 77.15% | 78.90% | 80.38% | 81.19% | 81.23% | 81.26% | 81.80% | 81.61% | 81.78% | 81.69% | 81.33% | 81.37% | 81.26% | 81.05% | 80.99% | 80.68% | 80.64% | 80.23% | 79.82% | — | — | — | |||||||
| Biogen Inc. | 87.97% | 87.47% | 86.40% | 85.97% | 85.59% | 85.72% | 86.50% | 86.12% | 86.43% | 86.57% | 86.72% | 87.34% | 86.80% | 86.56% | 87.08% | 87.46% | 88.21% | 88.65% | 88.48% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 69.59% | 68.08% | 69.10% | 69.65% | 69.93% | 70.77% | 70.98% | 70.37% | 70.12% | 69.62% | 70.80% | 71.92% | 72.78% | 74.19% | 74.54% | 75.56% | 75.55% | 75.67% | 76.39% | — | — | — | |||||||
| Eli Lilly & Co. | 78.67% | 79.22% | 78.85% | 77.78% | 76.67% | 74.96% | 73.81% | 73.39% | 72.92% | 72.95% | 73.46% | 73.69% | 73.89% | 73.78% | 73.35% | 73.23% | 73.72% | 74.39% | 74.76% | — | — | — | |||||||
| Gilead Sciences Inc. | 78.25% | 79.06% | 78.86% | 79.27% | 78.98% | 78.02% | 77.61% | 79.21% | 80.31% | 81.82% | 82.97% | 84.51% | 84.71% | 85.95% | 85.77% | 86.36% | 86.91% | 86.69% | 87.54% | — | — | — | |||||||
| Johnson & Johnson | 65.66% | 66.15% | 66.42% | 66.49% | 66.67% | 66.80% | 66.79% | 66.36% | 65.69% | 66.22% | 66.84% | 68.20% | 69.35% | 69.88% | 69.84% | 69.52% | 69.58% | 69.25% | 69.27% | — | — | — | |||||||
| Merck & Co. Inc. | 70.06% | 70.11% | 69.87% | 70.13% | 69.89% | 68.94% | 68.06% | 67.35% | 67.81% | 68.22% | 68.16% | 68.09% | 67.92% | 66.61% | 65.10% | 63.89% | 62.58% | 62.07% | 62.19% | — | — | — | |||||||
| Pfizer Inc. | 79.94% | 79.94% | 80.25% | 79.85% | 79.91% | 79.36% | 79.03% | 78.58% | 78.24% | 78.48% | 78.61% | 78.66% | 78.15% | 77.28% | 76.66% | 76.48% | 77.71% | 79.09% | 80.25% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 88.21% | 89.72% | 90.05% | 91.14% | 92.27% | 92.79% | 93.53% | 93.36% | 93.28% | 92.95% | 93.24% | 93.37% | 94.16% | 94.53% | 93.83% | 92.90% | 91.38% | 90.52% | 90.43% | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 87.71% | 87.24% | 86.84% | 86.60% | 86.56% | 86.74% | 86.56% | 86.88% | 87.31% | 87.59% | 88.95% | 89.04% | 89.08% | 89.76% | 87.64% | 87.16% | 87.72% | 87.39% | 87.94% | — | — | — | |||||||
| Zoetis Inc. | 69.73% | 69.51% | 68.18% | 67.38% | 66.92% | 66.49% | 67.19% | 68.12% | 68.04% | 67.31% | 66.55% | 65.14% | 64.91% | 65.30% | 65.92% | 65.32% | 64.90% | 64.08% | 63.53% | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Q2 2020 Calculation
Gross profit margin = 100
× (Gross profitQ2 2020
+ Gross profitQ1 2020
+ Gross profitQ4 2019
+ Gross profitQ3 2019)
÷ (RevenueQ2 2020
+ RevenueQ1 2020
+ RevenueQ4 2019
+ RevenueQ3 2019)
= 100 × (428 + 619 + 662 + 648)
÷ (633 + 859 + 952 + 907)
= 70.34%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Gross profit margin | Gross profit margin indicates the percentage of revenue available to cover operating and other expenditures. | Illumina Inc.’s gross profit margin ratio improved from Q4 2019 to Q1 2020 but then slightly deteriorated from Q1 2020 to Q2 2020. |
Operating Profit Margin
Illumina Inc., operating profit margin calculation (quarterly data)
| Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Jan 1, 2017 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | Jan 3, 2016 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Income from operations | 96 | 189 | 268 | 308 | 205 | 204 | 197 | 241 | 227 | 218 | 230 | 181 | 143 | 52 | 143 | 161 | 162 | 121 | 144 | 141 | 152 | 176 | |||||||
| Revenue | 633 | 859 | 952 | 907 | 838 | 846 | 868 | 853 | 830 | 782 | 778 | 714 | 662 | 598 | 619 | 607 | 600 | 572 | 592 | 550 | 539 | 539 | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| Operating profit margin1 | 25.69% | 27.28% | 27.80% | 26.42% | 24.88% | 25.58% | 26.49% | 28.25% | 27.58% | 26.29% | 22.02% | 20.01% | 20.06% | 21.35% | 24.48% | 24.80% | 24.55% | 24.77% | 27.61% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 12.78% | 14.18% | 14.21% | 13.74% | 13.27% | 12.31% | 11.94% | 10.45% | 10.11% | 8.92% | 6.30% | 7.89% | 8.77% | 11.03% | 15.27% | 14.74% | 13.95% | 13.64% | 14.05% | — | — | — | |||||||
| AbbVie Inc. | 30.17% | 39.86% | 39.03% | 20.04% | 21.85% | 19.88% | 19.49% | 32.99% | 32.84% | 34.03% | 33.99% | 37.24% | 36.74% | 36.33% | 36.60% | 36.21% | 35.00% | 34.18% | 32.97% | — | — | — | |||||||
| Amgen Inc. | 39.76% | 41.89% | 43.57% | 44.83% | 44.05% | 44.53% | 45.55% | 45.82% | 46.46% | 46.07% | 45.76% | 46.66% | 46.93% | 45.68% | 44.74% | 43.33% | 42.46% | 41.53% | 40.44% | — | — | — | |||||||
| Biogen Inc. | 50.93% | 51.03% | 48.98% | 47.13% | 46.90% | 42.40% | 43.77% | 44.67% | 45.58% | 46.49% | 43.54% | 40.25% | 38.72% | 41.59% | 44.99% | 47.59% | 47.86% | 47.11% | 45.44% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | 11.67% | 16.30% | 22.62% | 28.64% | 28.60% | 23.44% | 22.69% | 18.64% | 15.93% | 17.50% | 17.39% | 19.71% | 21.73% | 24.06% | 23.83% | 19.21% | 16.34% | 11.09% | 11.41% | — | — | — | |||||||
| Eli Lilly & Co. | 24.48% | 25.64% | 22.29% | 20.00% | 19.48% | 12.50% | 15.15% | 12.34% | 9.11% | 14.88% | 9.38% | 12.43% | 14.23% | 12.92% | 16.30% | 14.31% | 14.56% | 14.27% | 13.47% | — | — | — | |||||||
| Gilead Sciences Inc. | -4.40% | 19.89% | 19.38% | 19.71% | 38.44% | 37.87% | 37.83% | 42.81% | 46.25% | 51.51% | 55.04% | 58.72% | 58.71% | 58.46% | 58.87% | 61.67% | 63.83% | 66.22% | 69.03% | — | — | — | |||||||
| Johnson & Johnson | 24.64% | 25.62% | 24.15% | 24.15% | 22.63% | 22.69% | 24.27% | 22.59% | 23.05% | 23.63% | 24.07% | 27.02% | 28.55% | 28.83% | 28.72% | 26.37% | 25.66% | 25.00% | 25.05% | — | — | — | |||||||
| Merck & Co. Inc. | 25.40% | 25.49% | 24.77% | 25.56% | 26.73% | 24.38% | 19.62% | 17.84% | 12.28% | 13.57% | 16.28% | 9.92% | 16.85% | 14.45% | 13.51% | 19.60% | 18.10% | 18.19% | 17.54% | — | — | — | |||||||
| Pfizer Inc. | 23.75% | 25.38% | 25.46% | 26.30% | 27.50% | 26.86% | 26.10% | 26.18% | 26.00% | 25.86% | 25.92% | 24.69% | 23.57% | 22.94% | 22.73% | 22.96% | 24.02% | 24.86% | 24.20% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 34.64% | 30.45% | 28.10% | 29.55% | 29.58% | 35.41% | 37.77% | 37.00% | 36.89% | 36.54% | 35.41% | 34.22% | 32.29% | 28.76% | 27.38% | 25.67% | 26.77% | 29.26% | 30.51% | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 38.67% | 34.05% | 28.77% | 21.38% | 25.48% | 23.98% | 20.84% | 22.38% | 3.87% | -0.77% | 4.95% | 1.62% | 16.16% | 14.62% | 0.58% | -5.02% | -8.65% | -23.94% | -45.23% | — | — | — | |||||||
| Zoetis Inc. | 33.36% | 32.72% | 31.42% | 31.01% | 29.80% | 30.05% | 31.12% | 33.00% | 33.86% | 33.02% | 32.15% | 29.43% | 28.34% | 28.55% | 28.48% | 26.22% | 24.91% | 17.35% | 15.74% | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Q2 2020 Calculation
Operating profit margin = 100
× (Income from operationsQ2 2020
+ Income from operationsQ1 2020
+ Income from operationsQ4 2019
+ Income from operationsQ3 2019)
÷ (RevenueQ2 2020
+ RevenueQ1 2020
+ RevenueQ4 2019
+ RevenueQ3 2019)
= 100 × (96 + 189 + 268 + 308)
÷ (633 + 859 + 952 + 907)
= 25.69%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Operating profit margin | A profitability ratio calculated as operating income divided by revenue. | Illumina Inc.’s operating profit margin ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Net Profit Margin
Illumina Inc., net profit margin calculation (quarterly data)
| Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Jan 1, 2017 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | Jan 3, 2016 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Net income attributable to Illumina stockholders | 47 | 173 | 239 | 234 | 296 | 233 | 210 | 199 | 209 | 208 | 68 | 163 | 128 | 367 | 124 | 129 | 120 | 90 | 104 | 118 | 102 | 137 | |||||||
| Revenue | 633 | 859 | 952 | 907 | 838 | 846 | 868 | 853 | 830 | 782 | 778 | 714 | 662 | 598 | 619 | 607 | 600 | 572 | 592 | 550 | 539 | 539 | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| Net profit margin1 | 20.68% | 26.49% | 28.28% | 28.13% | 27.55% | 25.05% | 24.78% | 21.09% | 20.88% | 19.31% | 26.38% | 30.14% | 30.07% | 30.52% | 19.29% | 18.70% | 18.70% | 18.40% | 20.79% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 9.89% | 11.15% | 11.56% | 10.50% | 9.36% | 8.53% | 7.74% | 2.91% | 3.13% | 1.67% | 1.74% | 8.37% | 4.96% | 6.74% | 6.71% | 6.61% | 11.08% | 12.00% | 21.68% | — | — | — | |||||||
| AbbVie Inc. | 19.20% | 24.77% | 23.69% | 9.90% | 12.62% | 16.42% | 17.36% | 23.50% | 20.84% | 21.55% | 18.82% | 24.38% | 24.77% | 24.07% | 23.22% | 24.08% | 23.11% | 23.03% | 22.50% | — | — | — | |||||||
| Amgen Inc. | 31.53% | 33.64% | 35.32% | 36.14% | 35.57% | 35.93% | 37.25% | 9.96% | 10.72% | 10.11% | 9.08% | 37.36% | 37.24% | 36.12% | 35.27% | 35.19% | 34.48% | 33.86% | 33.13% | — | — | — | |||||||
| Biogen Inc. | 40.91% | 40.76% | 40.96% | 37.91% | 37.62% | 33.79% | 32.93% | 24.08% | 23.06% | 23.54% | 20.69% | 29.44% | 28.10% | 30.17% | 32.34% | 34.03% | 33.97% | 33.79% | 32.95% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | -1.61% | 3.08% | 13.15% | 23.39% | 26.00% | 22.09% | 21.81% | 6.50% | 1.74% | 4.37% | 4.85% | 20.56% | 22.66% | 24.22% | 22.94% | 18.22% | 16.29% | 9.31% | 9.45% | — | — | — | |||||||
| Eli Lilly & Co. | 24.48% | 23.97% | 37.27% | 35.10% | 33.76% | 26.12% | 13.16% | 1.85% | -0.60% | 4.82% | -0.89% | 9.90% | 11.12% | 10.13% | 12.90% | 11.73% | 11.97% | 11.49% | 12.07% | — | — | — | |||||||
| Gilead Sciences Inc. | -1.18% | 22.17% | 24.35% | 12.24% | 27.14% | 26.93% | 25.16% | 7.27% | 9.69% | 14.26% | 18.03% | 42.90% | 43.55% | 44.11% | 45.07% | 48.40% | 51.16% | 53.48% | 56.32% | — | — | — | |||||||
| Johnson & Johnson | 18.86% | 20.75% | 18.42% | 17.32% | 20.08% | 17.99% | 18.75% | 1.89% | 1.70% | 1.58% | 1.70% | 21.28% | 22.52% | 22.87% | 23.01% | 22.27% | 21.20% | 22.15% | 21.99% | — | — | — | |||||||
| Merck & Co. Inc. | 22.20% | 21.10% | 21.01% | 20.26% | 21.10% | 19.50% | 14.71% | 8.02% | 3.25% | 3.88% | 5.97% | 7.15% | 12.71% | 10.88% | 9.85% | 13.76% | 13.01% | 11.72% | 11.25% | — | — | — | |||||||
| Pfizer Inc. | 28.80% | 31.17% | 31.45% | 30.57% | 23.58% | 21.31% | 20.79% | 44.63% | 42.35% | 41.29% | 40.55% | 18.69% | 15.90% | 13.88% | 13.66% | 11.77% | 13.47% | 14.95% | 14.25% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 37.30% | 28.56% | 26.91% | 28.13% | 28.59% | 35.12% | 36.42% | 28.24% | 25.65% | 23.54% | 20.41% | 23.17% | 22.05% | 19.34% | 18.42% | 16.85% | 15.98% | 16.72% | 15.50% | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 38.51% | 31.35% | 28.27% | 59.23% | 64.13% | 66.01% | 68.80% | 22.87% | 15.84% | 9.36% | 10.59% | 8.53% | 12.19% | 8.78% | -6.58% | -13.17% | -17.66% | -30.91% | -53.89% | — | — | — | |||||||
| Zoetis Inc. | 25.50% | 25.41% | 23.96% | 23.76% | 22.74% | 23.47% | 24.52% | 20.35% | 19.95% | 17.97% | 16.28% | 18.29% | 17.50% | 17.25% | 16.80% | 14.10% | 13.15% | 7.83% | 7.11% | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Q2 2020 Calculation
Net profit margin = 100
× (Net income attributable to Illumina stockholdersQ2 2020
+ Net income attributable to Illumina stockholdersQ1 2020
+ Net income attributable to Illumina stockholdersQ4 2019
+ Net income attributable to Illumina stockholdersQ3 2019)
÷ (RevenueQ2 2020
+ RevenueQ1 2020
+ RevenueQ4 2019
+ RevenueQ3 2019)
= 100 × (47 + 173 + 239 + 234)
÷ (633 + 859 + 952 + 907)
= 20.68%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| Net profit margin | An indicator of profitability, calculated as net income divided by revenue. | Illumina Inc.’s net profit margin ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Return on Equity (ROE)
Illumina Inc., ROE calculation (quarterly data)
| Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Jan 1, 2017 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | Jan 3, 2016 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Net income attributable to Illumina stockholders | 47 | 173 | 239 | 234 | 296 | 233 | 210 | 199 | 209 | 208 | 68 | 163 | 128 | 367 | 124 | 129 | 120 | 90 | 104 | 118 | 102 | 137 | |||||||
| Total Illumina stockholders’ equity | 4,563 | 4,635 | 4,613 | 4,439 | 4,332 | 3,985 | 3,758 | 3,503 | 3,257 | 3,008 | 2,749 | 2,855 | 2,715 | 2,551 | 2,197 | 2,240 | 2,056 | 1,991 | 1,849 | 1,937 | 1,794 | 1,623 | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| ROE1 | 15.19% | 20.32% | 21.72% | 21.92% | 21.65% | 21.36% | 21.98% | 19.53% | 19.90% | 18.85% | 26.41% | 27.38% | 27.54% | 29.01% | 21.06% | 19.79% | 21.05% | 20.82% | 24.97% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 10.17% | 11.84% | 11.86% | 10.35% | 9.14% | 8.48% | 7.76% | 2.89% | 3.03% | 1.52% | 1.54% | 6.57% | 3.71% | 4.79% | 6.82% | 6.59% | 11.02% | 11.81% | 20.85% | — | — | — | |||||||
| AbbVie Inc. | 47.30% | — | — | — | — | — | — | — | — | 179.59% | 104.16% | 99.42% | 110.08% | 126.25% | 128.41% | 93.97% | 101.42% | 117.94% | 130.39% | — | — | — | |||||||
| Amgen Inc. | 68.48% | 80.92% | 81.07% | 73.83% | 73.73% | 74.55% | 67.15% | 15.35% | 15.86% | 14.21% | 7.84% | 25.37% | 25.77% | 25.76% | 25.85% | 24.65% | 24.67% | 25.16% | 24.71% | — | — | — | |||||||
| Biogen Inc. | 52.41% | 46.85% | 44.13% | 38.55% | 40.87% | 33.74% | 33.98% | 23.15% | 24.21% | 21.09% | 20.13% | 27.10% | 28.42% | 30.31% | 30.50% | 32.06% | 33.48% | 35.78% | 37.84% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | -1.15% | 1.91% | 6.66% | 32.04% | 38.65% | 33.80% | 35.07% | 10.50% | 3.05% | 7.18% | 8.58% | 28.61% | 31.20% | 33.55% | 27.55% | 21.56% | 19.24% | 10.94% | 10.97% | — | — | — | |||||||
| Eli Lilly & Co. | 137.26% | 179.72% | 319.09% | 234.97% | 282.08% | 252.24% | 32.88% | 3.44% | -1.24% | 7.74% | -1.76% | 14.94% | 17.35% | 15.58% | 19.54% | 15.68% | 16.85% | 15.45% | 16.53% | — | — | — | |||||||
| Gilead Sciences Inc. | -1.43% | 22.49% | 23.91% | 13.07% | 26.33% | 26.84% | 25.51% | 6.94% | 10.19% | 16.82% | 22.64% | 46.69% | 53.86% | 61.82% | 71.48% | 89.38% | 105.21% | 129.43% | 97.70% | — | — | — | |||||||
| Johnson & Johnson | 24.11% | 28.01% | 25.42% | 24.31% | 26.87% | 24.90% | 25.60% | 2.39% | 2.18% | 1.97% | 2.16% | 21.39% | 22.71% | 23.46% | 23.49% | 21.91% | 20.73% | 21.40% | 21.66% | — | — | — | |||||||
| Merck & Co. Inc. | 37.91% | 38.72% | 37.99% | 34.70% | 33.88% | 30.50% | 23.30% | 10.32% | 4.12% | 4.69% | 6.97% | 7.44% | 12.89% | 10.91% | 9.78% | 12.55% | 11.84% | 10.53% | 9.94% | — | — | — | |||||||
| Pfizer Inc. | 22.02% | 24.28% | 25.77% | 24.91% | 21.24% | 19.52% | 17.59% | 33.40% | 32.31% | 29.72% | 29.88% | 16.14% | 14.26% | 12.49% | 12.12% | 9.90% | 11.22% | 12.09% | 10.75% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 32.94% | 18.79% | 19.08% | 20.41% | 21.21% | 25.70% | 27.91% | 22.85% | 22.14% | 21.74% | 19.51% | 21.12% | 20.91% | 19.79% | 20.13% | 17.75% | 18.23% | 19.69% | 17.40% | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 27.67% | 23.38% | 19.34% | 40.81% | 43.70% | 45.63% | 47.28% | 22.27% | 15.46% | 9.41% | 12.99% | 10.93% | 15.55% | 11.82% | -9.69% | -21.41% | -28.03% | -41.73% | -59.19% | — | — | — | |||||||
| Zoetis Inc. | 54.23% | 58.52% | 55.39% | 54.56% | 57.03% | 59.91% | 65.35% | 54.96% | 56.60% | 49.90% | 48.81% | 47.11% | 51.20% | 53.14% | 55.21% | 43.47% | 47.09% | 32.45% | 31.74% | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Q2 2020 Calculation
ROE = 100
× (Net income attributable to Illumina stockholdersQ2 2020
+ Net income attributable to Illumina stockholdersQ1 2020
+ Net income attributable to Illumina stockholdersQ4 2019
+ Net income attributable to Illumina stockholdersQ3 2019)
÷ Total Illumina stockholders’ equity
= 100 × (47 + 173 + 239 + 234)
÷ 4,563 = 15.19%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROE | A profitability ratio calculated as net income divided by shareholders’ equity. | Illumina Inc.’s ROE deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |
Return on Assets (ROA)
Illumina Inc., ROA calculation (quarterly data)
| Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | Jan 1, 2017 | Oct 2, 2016 | Jul 3, 2016 | Apr 3, 2016 | Jan 3, 2016 | Sep 27, 2015 | Jun 28, 2015 | Mar 29, 2015 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||
| Net income attributable to Illumina stockholders | 47 | 173 | 239 | 234 | 296 | 233 | 210 | 199 | 209 | 208 | 68 | 163 | 128 | 367 | 124 | 129 | 120 | 90 | 104 | 118 | 102 | 137 | |||||||
| Total assets | 7,248 | 7,261 | 7,316 | 7,089 | 6,973 | 7,390 | 6,959 | 6,759 | 5,851 | 5,542 | 5,257 | 5,046 | 4,858 | 4,598 | 4,281 | 4,228 | 3,985 | 3,794 | 3,688 | 3,734 | 3,703 | 3,499 | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||
| ROA1 | 9.56% | 12.97% | 13.70% | 13.73% | 13.45% | 11.52% | 11.87% | 10.12% | 11.08% | 10.23% | 13.81% | 15.49% | 15.39% | 16.10% | 10.81% | 10.49% | 10.86% | 10.93% | 12.52% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||||||||
| Abbott Laboratories | 4.52% | 5.36% | 5.43% | 4.80% | 4.23% | 3.88% | 3.53% | 1.24% | 1.35% | 0.67% | 0.63% | 2.91% | 1.65% | 2.12% | 2.66% | 3.47% | 5.72% | 6.17% | 10.72% | — | — | — | |||||||
| AbbVie Inc. | 4.65% | 9.25% | 8.84% | 5.48% | 7.21% | 9.44% | 9.58% | 11.43% | 10.46% | 9.20% | 7.50% | 9.66% | 9.87% | 9.61% | 9.01% | 9.12% | 8.51% | 10.19% | 9.70% | — | — | — | |||||||
| Amgen Inc. | 11.23% | 12.45% | 13.13% | 13.55% | 13.40% | 12.62% | 12.64% | 3.27% | 3.49% | 3.12% | 2.48% | 10.18% | 10.27% | 10.14% | 9.95% | 9.71% | 9.85% | 9.61% | 9.69% | — | — | — | |||||||
| Biogen Inc. | 23.23% | 22.51% | 21.62% | 19.63% | 20.14% | 17.65% | 17.52% | 12.50% | 12.39% | 11.36% | 10.73% | 15.11% | 15.13% | 16.42% | 16.19% | 17.58% | 17.75% | 17.87% | 18.19% | — | — | — | |||||||
| Bristol-Myers Squibb Co. | -0.44% | 0.74% | 2.65% | 9.85% | 11.24% | 14.77% | 14.06% | 4.24% | 1.15% | 2.78% | 3.00% | 12.45% | 13.73% | 14.68% | 13.22% | 9.98% | 8.74% | 4.94% | 4.93% | — | — | — | |||||||
| Eli Lilly & Co. | 13.39% | 13.46% | 21.17% | 20.97% | 20.28% | 16.46% | 7.36% | 1.01% | -0.34% | 2.53% | -0.45% | 5.17% | 5.98% | 5.81% | 7.05% | 6.50% | 6.76% | 6.68% | 6.77% | — | — | — | |||||||
| Gilead Sciences Inc. | -0.46% | 8.31% | 8.74% | 4.55% | 9.42% | 9.38% | 8.57% | 2.47% | 3.38% | 5.30% | 6.58% | 17.94% | 20.27% | 21.90% | 23.70% | 26.63% | 32.71% | 36.30% | 34.93% | — | — | — | |||||||
| Johnson & Johnson | 9.59% | 11.07% | 9.59% | 9.10% | 10.53% | 9.78% | 10.00% | 0.99% | 0.88% | 0.79% | 0.83% | 10.17% | 10.69% | 11.39% | 11.71% | 11.36% | 10.75% | 11.41% | 11.55% | — | — | — | |||||||
| Merck & Co. Inc. | 11.56% | 11.95% | 11.66% | 11.18% | 11.15% | 10.20% | 7.53% | 3.93% | 1.58% | 1.84% | 2.72% | 3.11% | 5.48% | 4.50% | 4.11% | 5.58% | 5.32% | 4.67% | 4.36% | — | — | — | |||||||
| Pfizer Inc. | 7.96% | 9.49% | 9.72% | 9.51% | 8.10% | 7.38% | 7.00% | 14.19% | 13.67% | 13.21% | 12.40% | 5.70% | 4.94% | 4.32% | 4.20% | 3.51% | 4.13% | 4.68% | 4.16% | — | — | — | |||||||
| Regeneron Pharmaceuticals Inc. | 20.68% | 14.46% | 14.29% | 15.38% | 15.71% | 18.88% | 20.83% | 16.64% | 15.99% | 15.23% | 13.67% | 14.69% | 14.24% | 12.32% | 12.84% | 11.68% | 11.97% | 12.56% | 11.34% | — | — | — | |||||||
| Vertex Pharmaceuticals Inc. | 20.37% | 16.99% | 14.15% | 28.53% | 31.50% | 32.94% | 33.57% | 14.00% | 9.58% | 5.72% | 7.43% | 6.12% | 7.91% | 6.02% | -3.87% | -8.38% | -10.79% | -16.05% | -22.26% | — | — | — | |||||||
| Zoetis Inc. | 12.37% | 13.97% | 12.99% | 12.96% | 12.52% | 12.75% | 13.25% | 11.13% | 12.96% | 11.25% | 10.06% | 10.09% | 11.25% | 11.18% | 10.73% | 8.93% | 8.50% | 5.07% | 4.28% | — | — | — | |||||||
Based on: 10-Q (filing date: 2020-08-07), 10-Q (filing date: 2020-05-01), 10-K (filing date: 2020-02-11), 10-Q (filing date: 2019-10-25), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-04-26), 10-K (filing date: 2019-02-12), 10-Q (filing date: 2018-10-24), 10-Q (filing date: 2018-07-31), 10-Q (filing date: 2018-04-25), 10-K (filing date: 2018-02-13), 10-Q (filing date: 2017-10-25), 10-Q (filing date: 2017-08-03), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-14), 10-Q (filing date: 2016-11-08), 10-Q (filing date: 2016-08-02), 10-Q (filing date: 2016-05-09), 10-K (filing date: 2016-03-02), 10-Q (filing date: 2015-11-02), 10-Q (filing date: 2015-07-31), 10-Q (filing date: 2015-05-01).
1 Q2 2020 Calculation
ROA = 100
× (Net income attributable to Illumina stockholdersQ2 2020
+ Net income attributable to Illumina stockholdersQ1 2020
+ Net income attributable to Illumina stockholdersQ4 2019
+ Net income attributable to Illumina stockholdersQ3 2019)
÷ Total assets
= 100 × (47 + 173 + 239 + 234)
÷ 7,248 = 9.56%
2 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| ROA | A profitability ratio calculated as net income divided by total assets. | Illumina Inc.’s ROA deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020. |